Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthstream (HSTM) Gains from Sales and Divestitures (2017 - 2026)

Healthstream has reported Gains from Sales and Divestitures over the past 10 years, most recently at $198000.0 for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 13.14% to $198000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $198000.0 through Dec 2025, up 13.14% year-over-year, with the annual reading at $198000.0 for FY2025, 13.14% up from the prior year.
  • Gains from Sales and Divestitures was $198000.0 for Q4 2025 at Healthstream, up from $15000.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $198000.0 in Q4 2025 and troughed at $15000.0 in Q3 2025.
  • The 5-year median for Gains from Sales and Divestitures is $125000.0 (2022), against an average of $113875.0.
  • Year-over-year, Gains from Sales and Divestitures rose 2.22% in 2021 and then soared 33.7% in 2022.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $92000.0 in 2021, then soared by 33.7% to $123000.0 in 2022, then grew by 29.27% to $159000.0 in 2023, then rose by 10.06% to $175000.0 in 2024, then grew by 13.14% to $198000.0 in 2025.
  • Per Business Quant, the three most recent readings for HSTM's Gains from Sales and Divestitures are $198000.0 (Q4 2025), $15000.0 (Q3 2025), and $22000.0 (Q2 2025).